CLDN18.2 positive (75 percent or more, 2+ intensity or higher)
The CLDN18.2 expression threshold used when discussing a specific antibody therapy in stomach cancer.
Parent marker: CLDN18.2
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Clinical meaning
Expression above a certain threshold is the basis for discussing categories of antibodies targeting CLDN18.2, generally in advanced disease.
How this finding appears in a report
Requires reporting of staining percentage and intensity; reports that simply say positive or negative are not enough.
When therapy stops working
Reporting thresholds and standards are still evolving between laboratories.
What needs verification
- Complete variant name as written in the laboratory report.
- Examination methods and types of samples used.
- Examination dates were compared with ongoing therapy.
Marker context: CLDN18.2
CLDN18.2 status may make a specific category of antibody therapy worth discussing in advanced gastric cancer. Assessment thresholds and reporting standards are still evolving and may vary between facilities.
A negative result does not always mean absent
Summary
- Gen
- CLDN18
- Variant
- CLDN18.2 positif pada 75 persen sel atau lebih dengan intensitas 2+ atau lebih
- Alteration type
- Overexpression
- Discussed in
- Stomach Cancer
- Updated
- 2026-09-10
Other names in reports
CLDN18.2 positive
Drugs discussed
Treatment categories
Related guides
Sources
- NCI Dictionary of Cancer Terms(lembaga)
- ClinicalTrials.gov(registry)
Clinical trials
Studies mentioning marker CLDN18.2
Filtered from public study descriptions. Access status and site readiness remain unverified.
NCT07872722Phase 2Combination regimen
Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Stomach Cancer | biomarker: CLDN18.2 | Immunotherapy, Targeted therapy, Chemotherapy
Japan4 registry sites
Why this appears: Appears because it is recorded for Stomach Cancer, it mentions marker CLDN18.2, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07872722Not verified
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- CLDN18.2
Biomarker
Reason: Related through a biomarker
- Stomach Cancer
Cancer type
Reason: Related to this page
- Zolbetuximab
Drug
Reason: Related to this page
- Targeted therapy
Treatment category
Reason: Related to this page
To check
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.